Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$64.68 USD
+0.24 (0.37%)
Updated Jun 1, 2023 04:00 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Price, Consensus and EPS Surprise
BMY 64.68 +0.24(0.37%)
Will BMY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMY
The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More
Other News for BMY
Rose's Income Garden 78 Stock May Dividend And Transaction Review
Interesting BMY Put And Call Options For July 14th
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Bristol Myers (BMY)
Bristol Myers Squibb Co. stock rises Thursday, still underperforms market